異位性皮膚炎

Atopic Dermatitis

共 3 種介入成分有評級——按證據強度從高到低排序

🔬 實證評級速查
🟡 B 初步證據副乾酪乳桿菌 K71/LP33 × 異位性皮膚炎

白話說：有初步證據，但研究規模還小，別當成定論。

證據分數 58 分（滿分 100） 　·　發布狀態：可參考，但附帶但書

💊 留意藥物交互作用
這樣判讀，是參考了這些單位：
  • UK NHS 態度：未涵蓋
    展開原文引用
    「There's some evidence that probiotics may be helpful in some cases, such as helping to ease some symptoms of irritable bowel syndrome (IBS). But there's little evidence to support many health claims made about them. For example, there's no evidence to suggest that probiotics can help treat eczema.」
  • NIH Office of Dietary Supplements 態度：持保留
    展開原文引用
    「A review of 23 studies (1,919 participants) in which probiotics were tested for treating allergic rhinitis found some evidence that they may be helpful for improving symptoms and quality of life... because the studies tested different probiotics and measured different effects, no recommendations about the use of probiotics could be made.」
  • PubMed PMID 21269308· 2011 · RCT (double-blind) · n=34
    展開原文引用
    「Beneficial effect of a diet containing heat-killed Lactobacillus paracasei K71 on adult type atopic dermatitis」

評級由多源健康證據引擎彙整（FDA／EFSA／NHS／TFDA／WHO／PubMed／NIH ODS 等多個官方與權威來源）。 產製日期 2026-06-09 ·　版本 v10。本評級僅供衛教參考，不取代醫師診斷與處方。 · 📊 證據資料庫原始頁面

🔬 實證評級速查
🟠 C 薄弱證據鼠李糖乳桿菌 GG × 異位性皮膚炎

白話說：證據還很薄弱，不足以當成有效的療法。

證據分數 47 分（滿分 100） 　·　發布狀態：可參考，但附帶但書

🇹🇼 台灣有獨立規範
這樣判讀，是參考了這些單位：
  • 第三方營養資料庫（國際）
    展開原文引用
    「Probiotics are microorganisms that can have a positive effect on health. (Examine catalogs 'Probiotics' as an umbrella entry; specific strains like L. rhamnosus GG are not individually graded.)」
  • US FDA 態度：支持
    展開原文引用
    「GRN No. 231 — Notified Substance: Lactobacillus casei subsp. rhamnosus strain GG. Intended Use: Ingredient in term infant formula, at levels not to exceed 10^8 colony forming units per gram of powdered formula. Notifier: Mead Johnson & Company. Agency Response: FDA has no questions (closure date: May 29, 2008).」
  • EU EFSA 態度：持保留
    展開原文引用
    「The bacterial species L. rhamnosus (now Lacticaseibacillus rhamnosus) is considered by EFSA to be suitable for the qualified presumption of safety (QPS) approach to safety assessment. However, the EFSA Panel on Dietetic Products, Nutrition and Allergies concluded that a cause and effect relationship has not been established between the consumption of Lactobacillus rhamnosus GG (ATCC 53103, LGG)…」

評級由多源健康證據引擎彙整（FDA／EFSA／NHS／TFDA／WHO／PubMed／NIH ODS 等多個官方與權威來源）。 產製日期 2026-06-09 ·　版本 v7。本評級僅供衛教參考，不取代醫師診斷與處方。 · 📊 證據資料庫原始頁面

🔬 實證評級速查
🟠 C 薄弱證據益生菌 × 異位性皮膚炎

白話說：證據還很薄弱，不足以當成有效的療法。

證據分數 43 分（滿分 100） 　·　發布狀態：可參考，但附帶但書

🇹🇼 台灣有獨立規範💊 留意藥物交互作用
這樣判讀，是參考了這些單位：
  • US FDA 態度：持保留
    展開原文引用
    「FDA has not approved any probiotic product for use as a drug or biological product in infants of any age」
  • EU EFSA 態度：不支持
    展開原文引用
    「a cause and effect relationship had not been established between the consumption of a combination of bacterial strains and reduction of gastro-intestinal discomfort」
  • UK NHS 態度：持保留
    展開原文引用
    「There's some evidence that probiotics may be helpful in some cases, such as helping to ease some symptoms of irritable bowel syndrome (IBS). But there's little evidence to support many health claims made about them.」

評級由多源健康證據引擎彙整（FDA／EFSA／NHS／TFDA／WHO／PubMed／NIH ODS 等多個官方與權威來源）。 產製日期 2026-06-09 ·　版本 v9。本評級僅供衛教參考，不取代醫師診斷與處方。 · 查看此成分的完整評級 · 📊 證據資料庫原始頁面